Lurasidone Combats Schizophrenia Symptoms

Lurasidone Combats Schizophrenia Symptoms

lurasidoneLurasidone CAS# 367514-87-2, is an atypical antipsychotic medication. Also known as the brand name Latuda, lurasidone is an effectual treatment for the symptoms of schizophrenia. As a second generation antipsychotic, or SGA, lurasidone is available in 20, 40, 80 and 120 milligram tablets. Latuda was approved by the FDA in October of 2010 for the specific treatment of schizophrenia in adults. While lurasidone is not a cure for schizophrenia, it is a viable solution for symptom relief for the patients suffering from this devastating mental illness.

Several weeks may go by before the patient begins to feel the effects of lurasidone, so it is important that patients be aware that instant symptom relief is atypical. The tablet is typically taken once daily by mouth, with a meal of at least 350 calories. Six week treatment intervals are recommended as these have been studied and documented as safe and tolerable dosage periods. You should plan to reevaluate patients after each six week period to determine the efficacy of this medication. Common adverse effects were minimal, and included somnolence, akathisia, nausea and Parkinsonism. Five short-term studies were completed prior to its FDA approval and the results demonstrated success in each one. These 6-week studies included placebo controlled as well as active-control arms of olanzapine or quetiapine extended-release. Phase III clinical trials encompassed 3,000 adult participants, and a successful outcome was determined based on the measurement of degrees of positive and negative symptoms and indicators of overall patient function at the six week mark.

According to the National Institute of Mental Health approximately 2.4 million Americans are affected by schizophrenia. In most cases, schizophrenia will initially appear in men during their late teens or early 20s and in women during their 20s or early 30s. Continued research and development is needed to treat this often enigmatic illness.

LGM Pharma provides lurasidone for research and development purposes, and offers clients complete support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1).  Any patent infringement and resulting liability is solely at buyer risk.



  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service